## **Special Issue**

# Recent Advances in the Discovery and Development of Drugs for Civilization Diseases

## Message from the Guest Editors

In the 21st century, the century that makes all dreams come true, medicine will allow us to forget about pain, old age, and diseases. Nothing could be more wrong. Civilization diseases, otherwise known as lifestyle diseases, social diseases, or diseases of the 21st century include non-communicable diseases that spread around the world due to the development of civilization. In this Special Issue, we invite potential authors to submit manuscripts in the form of research articles, reviews, or communications that contribute to every aspect of medicinal chemistry, the discovery of new drugs for broadly understood civilization diseases, their synthesis, mechanisms of action, biological activity, and advances in drug dosage forms. This Special Issue will welcome original, high-quality scientific articles, reviews, and communications in the field of computational methods for drug design, i.e., in silico research, as well as synthetic and biochemical approaches in this topic.

### **Guest Editors**

Dr. Marcin Gackowski

Dr. Karolina Szewczyk-Golec

Dr. Renata Studzińska

## Deadline for manuscript submissions

closed (25 January 2025)



## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/177238

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





## **Pharmaceutica**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

#### Editor-in-Chief

#### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

### **Author Benefits**

### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

